OncoMatch/Clinical Trials/NCT02356653

Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

Is NCT02356653 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs) for leukemia.

Early Phase 1RecruitingChildren's Hospital of PhiladelphiaNCT02356653Data as of May 2026

Treatment: Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs) — The goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia IRB approved protocols that utilize CliniMACs technology for T depletion.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Lab requirements

Blood counts

per current institutional SOP

Kidney function

per current institutional SOP

Liver function

per current institutional SOP

Hematologic and Organ Function per current institutional SOP

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Children's Hospital of Philadelphia · Philadelphia, Pennsylvania

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify